Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine
- 1 November 2010
- journal article
- research article
- Published by Taylor & Francis Ltd in Human Vaccines
- Vol. 6 (11), 906-914
- https://doi.org/10.4161/hv.6.11.12854
Abstract
A randomized, double-blind, study was conducted to evaluate the safety, tolerability and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) co-administered with live attenuated yellow fever vaccine (YF-17D strain; Stamaril®, Sanofi Pasteur) or administered successively. Participants (n = 108) were randomized to receive: YF followed by JE-CV 30 days later, JE followed by YF 30 days later, or the co-administration of JE and YF followed or preceded by placebo 30 days later or earlier. Placebo was used in a double-dummy fashion to ensure masking. Neutralizing antibody titers against JE-CV, YF-17D and selected wild-type JE strains was determined using a 50% serum-dilution plaque reduction neutralization test. Seroconversion was defined as the appearance of a neutralizing antibody titer above the assay cut-off post-immunization when not present pre-injection at day 0, or a least a four-fold rise in neutralizing antibody titer measured before the pre-injection day 0 and later post vaccination samples. There were no serious adverse events. Most adverse events (AEs) after JE vaccination were mild to moderate in intensity, and similar to those reported following YF vaccination. Seroconversion to JE-CV was 100% and 91% in the JE/YF and YF/JE sequential vaccination groups, respectively, compared with 96% in the co-administration group. All participants seroconverted to YF vaccine and retained neutralizing titers above the assay cut-off at month six. Neutralizing antibodies against JE vaccine were detected in 82-100% of participants at month six. These results suggest that both vaccines may be successfully co-administered simultaneously or 30 days apart.Keywords
This publication has 18 references indexed in Scilit:
- Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax™-JE experimental vaccineVaccine, 2004
- Chimeric Live, Attenuated Vaccine against Japanese Encephalitis (ChimeriVax‐JE): Phase 2 Clinical Trials for Safety and Immunogenicity, Effect of Vaccine Dose and Schedule, and Memory Response to Challenge with Inactivated Japanese Encephalitis AntigenThe Journal of Infectious Diseases, 2003
- New initiatives for the control of Japanese encephalitis by vaccination:: Minutes of a WHO/CVI meeting, Bangkok, Thailand, 13–15 October 1998Vaccine, 2000
- Recombinant, chimaeric live, attenuated vaccine (ChimeriVax™) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primatesVaccine, 1999
- Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control studyThe Lancet, 1996
- Japanese Encephalitis Vaccine: Persistence of Antibody up to 3 Years after a Three-Dose Primary SeriesThe Journal of Infectious Diseases, 1995
- Homologous and heterologous neutralization antibody responses after immunization with Japanese encephalitis vaccine among Taiwan childrenJournal of Medical Virology, 1994
- Adverse reactions to Japanese encephalitis vaccineThe Lancet, 1991
- Protection against Japanese Encephalitis by Inactivated VaccinesThe New England Journal of Medicine, 1988
- Japanese Encephalitis VaccinePediatrics International, 1988